This article studies the ethical implications of germinal human genome
modification. The need for such ethical consideration has been underscored by realworld
developments, as Dr He Jiankui, who announced in 2018 the first gene-edited
infants using CRISPR/Cas9 technology for germline modifications, has returned to
genetic practice after his 2022 prison release. The paper traces humanity's historical
pursuit of knowledge that pushed boundaries from ancient mythology through
medieval alchemy to the most recent developments in genomic engineering. The
study contrasts philosophical perspectives, utilitarian and transhumanist arguments
in support of genetic intervention with deontological and bioconservative objections
that emphasize human dignity and the moral value of genetic unpredictability. The
study also looks at ethical concerns such as fair access to genetic technologies, the
risk of increasing social inequalities, and the effects on human identity. It considers
how genetic enhancements might shift competitive sports from celebrating natural
ability to exhibits of biotechnology advancements. While acknowledging risks of
fundamental transformations to human identity and social structures, the article
also recognizes benefits such as health improvement, hereditary disease reduction
or increased human cognitive ability. The article concludes that human genome
modification represents an unprecedented technological development, which
requires careful navigation to achieve a global ethical consensus between the world
of medicine, ethics, and society. A consensus inspired by the 1975 Asilomar
conference, to preserve therapeutic applications while establishing safeguards
against potential abuses.
Keywords: Genetic modification ethics; Bioethics; Human genome modification;
Genetic inequality; Genetic doping